3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Melanoma
71
Neoplasms
10
Skin Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
2
Brain Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Skin Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Laryngeal Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
spartalizumab
1
sargramostim
1
dabrafenib
1
cobimetinib
1
aldesleukin
1
Vemurafenib
1
PLX8394
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
Vemurafenib
×
Dermatologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled